Omalizumab (Xolair) for treatment of asthma.
Davydov
Liya
L
Arnold and Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, Brooklyn, New York, USA.
D018927:Anti-Asthmatic Agents / Q000191:economics / Q000494:pharmacology*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000191:economics / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D000069444:Omalizumab
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab